Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Eli Lilly and Company

Revenue

Revenue %Chg

Revenue Common Size

Cost of Sales

Cost of Sales %Chg

Cost of Sales Common Size

Research and Development

Research and Development %Chg

Research and Development Common Size

Marketing, Selling and Administrative

Marketing, Selling and Administrative %Chg

Marketing, Selling and Administrative Common Size

Acquired IPR&D

Acquired IPR&D %Chg

Acquired IPR&D Common Size

Asset Impairment, Restructuring and Other Special Charges

Asset Impairment, Restructuring and Other Special Charges %Chg

Asset Impairment, Restructuring and Other Special Charges Common Size

Other-Net, Expense

Other-Net, Expense %Chg

Other-Net, Expense Common Size

Total Costs, Expenses, and Other

Total Costs, Expenses, and Other %Chg

Total Costs, Expenses, and Other Common Size

Income Before Income Taxes

Income Before Income Taxes %Chg

Income Before Income Taxes Common Size

Income Tax Expense

Income Tax Expense %Chg

Income Tax Expense Common Size

Net Income from Continuing Operations

Net Income from Continuing Operations %Chg

Net Income from Continuing Operations Common Size

Net Income from Discontinued Operations

Net Income from Discontinued Operations %Chg

Net Income from Discontinued Operations Common Size

Net Income

Net Income %Chg

Net Income Common Size

Earnings from Continuing Operations - Basic

Earnings from Continuing Operations - Basic %Chg

Earnings from Continuing Operations - Basic Common Size

Earnings from Discontinued Operations - Basic

Earnings from Discontinued Operations - Basic %Chg

Earnings from Discontinued Operations - Basic Common Size

Basic Earnings per Share

Basic Earnings per Share %Chg

Basic Earnings per Share Common Size

Earnings from Continuing Operations - Diluted

Earnings from Continuing Operations - Diluted %Chg

Earnings from Continuing Operations - Diluted Common Size

Earnings from Discontinued Operations - Diluted

Earnings from Discontinued Operations - Diluted %Chg

Earnings from Discontinued Operations - Diluted Common Size

Earnings per Share - Diluted

Earnings per Share - Diluted %Chg

Earnings per Share - Diluted Common Size

Dividends Paid per Share

Dividends Paid per Share %Chg

Dividends Paid per Share Common Size

Basic

Basic %Chg

Basic Common Size

Weighted-Average Shares Outstanding - Diluted

Weighted-Average Shares Outstanding - Diluted %Chg

Weighted-Average Shares Outstanding - Diluted Common Size

Total Revenues

Total Revenues %Chg

Total Revenues Common Size

Gross Profit

Gross Profit %Chg

Gross Profit Common Size

Gross Profit Margin

Gross Profit Margin %Chg

Gross Profit Margin Common Size

Selling, General & Administrative Expenses

Selling, General & Administrative Expenses %Chg

Selling, General & Administrative Expenses Common Size

Research & Development Expenses

Research & Development Expenses %Chg

Research & Development Expenses Common Size

Other Operating Expenses

Other Operating Expenses %Chg

Other Operating Expenses Common Size

Operating Profit

Operating Profit %Chg

Operating Profit Common Size

Operating Margin

Operating Margin %Chg

Operating Margin Common Size

Non-Operating Income

Non-Operating Income %Chg

Non-Operating Income Common Size

Total Non-Operating Income

Total Non-Operating Income %Chg

Total Non-Operating Income Common Size

Income Before Provision for Income Taxes

Income Before Provision for Income Taxes %Chg

Income Before Provision for Income Taxes Common Size

Provision for Income Taxes

Provision for Income Taxes %Chg

Provision for Income Taxes Common Size

Consolidated Net Income

Consolidated Net Income %Chg

Consolidated Net Income Common Size

Net Income Attributable to Discontinued Operations

Net Income Attributable to Discontinued Operations %Chg

Net Income Attributable to Discontinued Operations Common Size

Net Income Attributable to Common Shareholders

Net Income Attributable to Common Shareholders %Chg

Net Income Attributable to Common Shareholders Common Size

Basic EPS

Basic EPS %Chg

Basic EPS Common Size

Diluted EPS

Diluted EPS %Chg

Diluted EPS Common Size

Basic Weighted Average Shares Outstanding

Basic Weighted Average Shares Outstanding %Chg

Basic Weighted Average Shares Outstanding Common Size

Total Shares Outstanding

Total Shares Outstanding %Chg

Total Shares Outstanding Common Size

Diluted Weighted Average Shares Outstanding

Diluted Weighted Average Shares Outstanding %Chg

Diluted Weighted Average Shares Outstanding Common Size

EBITDA

EBIT

CapEx

Net Interest Income

Assets

Adjusted EBITDA

Adjusted Net Income

Net Revenue

Average Assets

Adjusted EBIT

Adjusted Revenue

Adjusted EBT

Adjusted Funds From Operations

Income Statement	Jun '25	Dec '24	Jun '24	Dec '23	Jun '23	Dec '22
Total Revenues	28,286.2	24,971.9	20,070.8	18,852	15,272.1	14,243.4
Total Revenues %Chg	40.9%	32.5%	31.4%	32.4%	6.8%	-3.6%
Revenue
Cost of Sales	4,672	4,574.6	3,843.7	3,648.1	3,434.1	3,127.2
Cost of Sales
Gross Profit	23,614.2	20,397.3	16,227.1	15,203.9	11,838	11,116.2
Gross Profit Margin	83.5%	81.7%	80.8%	80.6%	77.5%	78%
Selling, General & Administrative Expenses	5,221.8	4,524.3	4,069.5	3,728.5	3,674.6	3,257.4
Marketing, Selling and Administrative
Research & Development Expenses	7,795.3	8,772.2	5,498.8	8,569.5	4,543.7	4,101.3
Research and Development
Acquired IPR&D
Other Operating Expenses	35	425.6	435	67.7	—	244.6
Asset Impairment, Restructuring and Other Special Charges
Operating Profit	10,562.1	6,675.2	6,223.8	2,838.2	3,619.7	3,512.9
Operating Margin	37.3%	26.7%	31%	15.1%	23.7%	24.7%
Non-Operating Income	-329.6	-48.1	-170.5	97.8	-1.1	149
Other-Net, Expense
Total Non-Operating Income	-329.6	-48.1	-170.5	97.8	-1.1	149
Income Before Provision for Income Taxes	10,232.5	6,627.1	6,053.3	2,936	3,618.6	3,661.9
Income Before Income Taxes
Provision for Income Taxes	1,812.7	1,247	843.4	803.7	510.5	272.5
Income Tax Expense
Consolidated Net Income	8,419.8	5,380.1	5,209.9	2,132.3	3,108.1	3,389.4
Net Income from Continuing Operations
Net Income Attributable to Discontinued Operations	—	—	—	—	—	—
Net Income from Discontinued Operations
Net Income Attributable to Common Shareholders	8,419.8	5,380.1	5,209.9	2,132.3	3,108.1	3,389.4
Net Income
Basic EPS	9.4	6	5.8	2.4	3.5	3.8
Diluted EPS	9.4	6	5.8	2.4	3.4	3.7
Basic Weighted Average Shares Outstanding	898.3	900.4	900.8	900.1	900.3	901.5
Total Shares Outstanding	947.2	947.5	950.4	949.4	949.3	950.2
Diluted Weighted Average Shares Outstanding	900.2	904.1	904	903.6	903	904.8
EBITDA	11,503.4	7,626.8	7,038.8	3,636.9	4,348.3	4,250.8
Effective Tax Rate	17.7%	18.8%	13.9%	27.4%	14.1%	7.4%